Daily Archives: June 16, 2022
Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma
June 16th, 2022 LymphomaJune 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL).The approval was.... Read More
Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications
June 16th, 2022 UncategorizedJune 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration has approved the following:In combination with fluoropyrimidine- and platinum-based che.... Read More
Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia
June 16th, 2022 LeukemiaJune 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older with a susceptible .... Read More
Azacitidine is approved by FDA for newly diagnosed juvenile myelomonocytic leukemia
June 16th, 2022 Blood cancer, LeukemiaJune 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML).The pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine prior to hematop.... Read More